Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes

Cancer Immunology Immunotherapy

Volumn 47, Issue 5, 1999, Pages 278-286

  Haynes, Nicole M ^a   Smyth, Mark J ^a   Kershaw, Michael H ^a   Trapani, Joseph A ^a   Darcy, Phillip K ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Breast carcinoma; Fas ligand; Immunotherapy; Redirected cytotoxicity; Single chain antibody

Indexed keywords

CD8 ANTIGEN; CHIMERIC PROTEIN; FAS LIGAND; FC RECEPTOR; GAMMA INTERFERON; MONOCLONAL ANTIBODY; ONCOPROTEIN;

ARTICLE; BREAST CARCINOMA; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; PRIORITY JOURNAL; TARGET CELL DESTRUCTION;

ANIMALS; ANTIGENS, CD95; ANTIGENS, SURFACE; COS CELLS; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASMS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032949539     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050532     Document Type: Article

References (44)

1. 1. Altenschmidt U, Kahl R, Moritz D, Schnierie BS, Gerstmayer B, Wels W, Groner B (1996) Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3 and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Can Res 2:1001
2. 2. Altenschmidt U, Kludt E, Groner B (1997) Adoptive immunotherapy of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 159:5509
3. 3. Aruffo A, Seed B (1987) Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci USA 84:8573
4. 4. Blottiere HM, Zennadi R, Gregoire M, Aillet G, Denis MG, Meflah K, Le Pendu J (1993) Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells. Int J Cancer 53:409
5. 5. Brocker T, Riedinger M, Karjalainen K (1996) Redirecting the complete T cell receptor/CD3 signalling machinery towards native antigen via modified T cell receptor. Eur J Immunol 26:1770
6. 6. Conzelmann A, Corthesy P, Cianfriglia M, Silvia A, Nabholz M (1982) Hybrids between rat lymphoma and mouse T cells with inducible cytolyic activity. Nature 298:170
7. 7. Darcy PK, Kershaw MH, Trapani JA, Smyth MJ (1998) Cytotoxic T lymphocyte expression of a single chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 28:1663
8. 8. Drebin JA, Link VC, Greene MI (1988) Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2:387
9. 9. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ (1996) Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 156:2693
10. 10. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720
11. 11. Foster BJ, Kern JA (1997) HER2-targeted gene transfer. Hum Gene Ther 8:719
12. 12. Fujimori K, Covell DG, Fletcher JE, Weinstein JN (1989) Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2 and Fab in tumors. Cancer Res 49:5656
13. 13. Garrido MA, Perez P, Titus JA, Valdayo MJ, Winkler DF, Barbieri SA, Wunderlich JR, Segal DM (1990) Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol 144:2891
14. 14. Gillott DJ, Nouri AM, Compton SJ, Oliver RT (1993) Accurate and rapid assessment of MHC antigen upregulation following cytokine stimulation. J Immunol Methods 165:231
15. 15. Hege KM, Cooze KS, Finer MH, Zsebo K, Roberts MR (1996) Systemic T cell-independent tumour immunity and transplantation of universal receptor-modified bone marrow into SCID mice. J Exp Med 184:2261
16. 16. Helgason CD, Prendergast JA, Berke G, Bleackley RC (1992) Peritoneal exudate lymphocyte and mixed lymphocyte culture hybridoma are cytolytic in the absence of cytotoxic cell proteinases and perforin. Eur J Immunol 22:3187
17. 17. Henkart PA (1994) Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343
18. 18. Hudziak RM, Lewis GD, Kinget M, Fendly BM, Shepard HM, Ullrich A (1989) p185HER2 monoclonal antibody has anti-proliferative effects in vitro and sensitized human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165
19. 19. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 178:361
20. 20. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA (1995) In vivo anti-tumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369
21. 21. Hynes NE (1993) Amplification and over-expression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor and potential as a target for cancer therapy. Semin Cancer Biol 4:19
22. 22. Hynes NE, Stern DF (1994) The biology of the erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165
23. 23. Ishida T, Tsujisaki M, Hinoda Y, Imai K, Yachi A (1994) Establishment and characterization of mouse-human chimeric monoclonal antibody to erbB-2 product. Jpn J Cancer Res 85:172
24. 24. Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81:570
25. 25. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S (1996) Fas expression and function in normal and malignant breast cell line. Cancer Res 56:4791
26. 26. Kershaw MH, Darcy PK, Trapani JA, Smyth MJ (1996) The use of chimeric human Fc (epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors. J Leukoc Biol 60:721
27. 27. Kershaw MH, Trapani JA, Smyth MJ (1995) Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 2:173
28. 28. Koshiji M, Adachi Y, Sogo S, Taketani S, Oyaizu N, Than S, Inaba M, Phawa S, Hioki K, Ikehara S (1998) Apoptosis of colorectal adenocarcinoma (COLO 201) by tumor necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression. Clin Exp Immunol 111:211
29. 29. Mobus VJ, Asphal W, Knapstein PG, Kreienberg R (1993) Effects of Interferon gamma on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 120:27
30. 30. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, Krammer PH (1994) Expression of APO-1 (CD95), a member of the neoplastic colon epithilium. Int J Cancer 57:371
31. 31. Moritz D, Groner B (1995) A spacer region between the single chain antibody and the CD3 ζ chain domain of chimeric T cell receptor components is required for efficient ligand binding and signalling activity. Gene Ther 8:539
32. 32. Moritz D, Wels W, Mattern J, Groner B (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 91:4318
33. 33. Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert JR, Shekhtman EM, Tomei LD, Umansky SR, Kiefer MC (1997) Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 272:16351
34. 34. Owen-Schaub LB, Meterissian S, Ford RJ (1993) Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J Immunother 14:234
35. 35. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S (1994) Anti-Fas on nonhaematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54:1580
36. 36. Renner C, Jun W, Sahin U, Lier R van, Pfreundschuh M (1995) The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 25:2027
37. 37. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J (1995) Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 17:51
38. 38. Rosenberg SA (1992) Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180
39. 39. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676
40. 2+-independent cell-mediated cytotoxicity. J Exp Med 177:195
41. 41. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z (1993) Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151:6577
42. 42. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S (1995) Expression of the Fas ligand in cells of T cell lineage. J Immunol 154:3806
43. 43. Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL (1996) Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 157:836
44. 44. Yang Y, Xiang Z, Ertl HC, Wilson JM (1995) Upregulation of class I major histocompatibility complex antigens by Interferon gamma is necessary for T-cell mediated elimination of recombinant adenovirus-infected heptocytes in vivo. Proc Natl Acad Sci USA 92:7257